Johnson & Johnson Chief Executive Joaquin Duato said on Tuesday that tariffs on pharmaceuticals can create supply chain ...

A drug inspired by the anesthetic ketamine just became the first new kind of depression medication in 35 years. Called Spravato, a brand name for esketamine, and developed by Johnson & Johnson ...

Johnson & Johnson is ending the phase 3 VENTURA ... trials was the change from baseline to day 43 in Montgomery-Åsberg Depression Rating Scale total score. Detailed results from the phase 3 ...

Johnson & Johnson stock slipped Tuesday, even after the company reported first-quarter earnings that surpassed expectations and boosted its full-year sales forecast. The pharmaceutical and biotech ...

She could not handle Johnson's continued infidelity, his abusive behavior and the hostile reaction of the public, and her bouts of depression gradually deepened. In December of 1910, Johnson began ...

Johnson & Johnson has achieved a significant milestone in depression treatment as the FDA granted expanded approval for Spravato as a monotherapy for treatment-resistant depression. The ...